skip to content

Cambridge Stem Cell Institute



Dr Richardson is a CRUK Clinician Scientist and Leukaemia UK John Goldman Fellow studying B-cell Acute Lymphoblastic Leukaemia (B-ALL), the commonest cancer in children. Dr Richardson studied Medical Sciences and Pharmacology at the University of Cambridge before completing clinical training at the University of Oxford, where he was awarded the George Pickering Prize for best performance in medical finals. He undertook a PhD at the CRUK UCL Cancer Institute, where he discovered and characterised unique human immune cell progenitors that are a likely origin of childhood B-ALL. His current projects are modelling the disordered epigenetic and stem cell states underlying high-risk B-ALL, alongside using cutting edge functional genomics screening and systems biology to develop novel therapeutic approaches.


Key publications: 

Wray JP et al. 2022 Nature Communications. Cell cycle corruption in a preleukemic ETV6-RUNX1 model exposes RUNX1 addiction as a therapeutic target in acute lymphoblastic leukemia. (In press)

Peña OA et al. 2021 Blood Advances. TLR7 ligation augments haematopoiesis in Rps14 (uS11) deficiency via paradoxical suppression of inflammatory signalling and enhanced differentiation.

Richardson SE & Huntly BJP. 2021 HemaSphere Targeting Chromatin Regulation in high-risk AML.

Richardson SE et al. 2021 STAR Protocols. In vitro differentiation of human pluripotent stem cells into the B lineage using OP9-MS5 co-culture.

Pocock R et al. 2021 British Journal of Haematology. Current and Emerging Therapeutic Approaches for T-cell Acute Lymphoblastic Leukaemia.

Leon TE et al. 2020 Cancer Discovery. EZH2 deficient T-cell acute lymphoblastic leukemia is sensitized to CHK1 inhibition through enhanced replication stress.

Beedham W et al. 2019 Clinical Medicine. Head injury in the elderly – an overview for the physician.

Richardson SE et al. 2019 HemaSphere. Intensive chemotherapy is associated with poor overall survival in autoimmune disease-associated myeloid malignancies.

Mathew NR et al. 2018 Nature Medicine. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells.

Böiers C*, Richardson SE* et al. 2018 Developmental Cell. A human IPS model implicates embryonic B-myeloid fate restriction as a developmental susceptibility to B acute lymphoblastic leukemia-associated ETV6-RUNX1. *Joint first author, alphabetically listed

Böiers C et al. 2015 Hematology Education: the education program for the annual congress of the European Hematology Association. Novel oncogenetic pathways in ALL.

Richardson SE et al. 2014 Lymphoma and Chronic Lymphocytic Leukaemias. The Role of Functional Imaging in Lymphoma: Current Controversies and Future Directions.

Richardson SE et al. 2013 British Journal of Haematology. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.

Richardson SE. 2013 Disease Models and Mechanisms. Modelling how initiating and transforming oncogenes cooperate to produce a leukaemic cell state.

Richardson SE et al. 2012 Leukaemia & Lymphoma. Routine bone marrow biopsy is not necessary in the staging of Hodgkin lymphoma (CHL) patients in the FDG-PET era.

Richardson SE & McNamara C. 2011 Advances in Haematology. The management of classical Hodgkin’s lymphoma: past, present and future.

Richardson S et al. 2009 Br. J. Haematology. Improving the management of neutropenic sepsis in the emergency department.

Yang C-H at al. 2006 ChemBioChem. Unusually Strong Positive Cooperativity in Binding of Peptides to Latent Membrane Protein-1 DNA Fragments of the Epstein-Barr Viral Gene.

Senior Clinical Research Associate & Honorary Consultant Haematologist (Huntly Group)
Simon Richardson
Not available for consultancy